


PHARMACEUTICAL 2019

Evolus Inc. Rank 134 of 371









PHARMACEUTICAL 2019

Evolus Inc. Rank 134 of 371



The relative strengths and weaknesses of Evolus Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evolus Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 100% points. The greatest weakness of Evolus Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is -75%, being 256% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	94,339
Cost of Goods Sold	0
Intangible Assets	77,276
Liabilities, Current	5,276
Liabilities, Non-Current	0
Other Assets	229
Other Compr. Net Income	0
Other Expenses	11,437
Other Liabilities	82,184
Other Net Income	203
Property and Equipment	0
Research and Development	6,487
Revenues	0
Selling, General and Administrative Expense	29,146

Output Variable	Value in 1000 USD
Assets	171,844
Liabilities	87,460
Expenses	47,070
Stockholders Equity	84,384
Net Income	-46,867
Comprehensive Net Income	-46,867
Economic Capital Ratio	-75%

